194 related articles for article (PubMed ID: 37845576)
21. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs.
Couvelard A; Cros J
Virchows Arch; 2022 Jun; 480(6):1129-1148. PubMed ID: 35278097
[TBL] [Abstract][Full Text] [Related]
22. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
[TBL] [Abstract][Full Text] [Related]
23. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
24. Relation between WHO Classification and Location- and Functionality-Based Classifications of Neuroendocrine Neoplasms of the Digestive Tract.
Helderman NC; Suerink M; Kilinç G; van den Berg JG; Nielsen M; Tesselaar MET
Neuroendocrinology; 2024; 114(2):120-133. PubMed ID: 37690447
[TBL] [Abstract][Full Text] [Related]
25. Angiogenic factors as prognostic markers in neuroendocrine neoplasms.
Puliani G; Sesti F; Anastasi E; Verrico M; Tarsitano MG; Feola T; Campolo F; Di Gioia CRT; Venneri MA; Angeloni A; Appetecchia M; Lenzi A; Isidori AM; Faggiano A; Giannetta E;
Endocrine; 2022 Apr; 76(1):208-217. PubMed ID: 35088292
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study.
Zheng Z; Chen C; Jiang L; Zhou X; Dai X; Song Y; Li Y
Cancer Med; 2019 Dec; 8(17):7288-7298. PubMed ID: 31609098
[TBL] [Abstract][Full Text] [Related]
27. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.
Liu M; Zhang Y; Chen L; Lin Y; He Q; Zeng Y; Chen M; Chen J
Endocrine; 2021 Jan; 71(1):242-252. PubMed ID: 33010002
[TBL] [Abstract][Full Text] [Related]
28. Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications.
Vitale G; Carra S; Ferraù F; Guadagno E; Faggiano A; Colao A;
Crit Rev Oncol Hematol; 2020 Feb; 146():102840. PubMed ID: 31918344
[TBL] [Abstract][Full Text] [Related]
29. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
31. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas.
Patel N; Barbieri A; Gibson J
Surg Pathol Clin; 2019 Dec; 12(4):1021-1044. PubMed ID: 31672292
[TBL] [Abstract][Full Text] [Related]
33. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
34. Molecular Imaging of Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2662-e2670. PubMed ID: 35380158
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.
Strzelczyk J; Wójcik-Giertuga M; Cuber P; Biernacki K; Kos-Kudła B; Strzelczyk JK
Biomed Res Int; 2022; 2022():9084393. PubMed ID: 35372578
[TBL] [Abstract][Full Text] [Related]
36. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
38. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
Albers MB; Almquist M; Bergenfelz A; Nordenström E
Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
[TBL] [Abstract][Full Text] [Related]
39. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Merola E; Panzuto F; Delle Fave G
Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
[TBL] [Abstract][Full Text] [Related]
40. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
